WO1997023477A1 - Derives de dibenzothiepine et compositions pharmaceutiques - Google Patents

Derives de dibenzothiepine et compositions pharmaceutiques Download PDF

Info

Publication number
WO1997023477A1
WO1997023477A1 PCT/EP1996/005631 EP9605631W WO9723477A1 WO 1997023477 A1 WO1997023477 A1 WO 1997023477A1 EP 9605631 W EP9605631 W EP 9605631W WO 9723477 A1 WO9723477 A1 WO 9723477A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
compound
relapse
schizophrenic patients
formula
Prior art date
Application number
PCT/EP1996/005631
Other languages
English (en)
Inventor
Stephen Jason Cooper
David John King
Joher Raniwalla
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Priority to EP96943126A priority Critical patent/EP0874840A1/fr
Priority to AU11955/97A priority patent/AU1195597A/en
Publication of WO1997023477A1 publication Critical patent/WO1997023477A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D337/14—[b,f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un composé de la formule (I), ou un sel acceptable sur le plan pharmaceutique de celui-ci, dans laquelle R1 et R2 sont, d'une manière indépendante H ou méthyle (par exemple 2-[(8-chlorodibenzo[b,f]thiépin-10-yl)oxy]-N,N-diméthyléthylamine); ledit composé est utilisé pour empêcher les rechutes chez des patients atteints de schizophrénie chronique.
PCT/EP1996/005631 1995-12-21 1996-12-16 Derives de dibenzothiepine et compositions pharmaceutiques WO1997023477A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96943126A EP0874840A1 (fr) 1995-12-21 1996-12-16 Derives de dibenzothiepine et compositions pharmaceutiques
AU11955/97A AU1195597A (en) 1995-12-21 1996-12-16 Dibenzothiepin derivatives and pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9526264.8 1995-12-21
GBGB9526264.8A GB9526264D0 (en) 1995-12-21 1995-12-21 Medical treatment

Publications (1)

Publication Number Publication Date
WO1997023477A1 true WO1997023477A1 (fr) 1997-07-03

Family

ID=10785883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005631 WO1997023477A1 (fr) 1995-12-21 1996-12-16 Derives de dibenzothiepine et compositions pharmaceutiques

Country Status (6)

Country Link
EP (1) EP0874840A1 (fr)
AU (1) AU1195597A (fr)
GB (1) GB9526264D0 (fr)
HR (1) HRP960600A2 (fr)
WO (1) WO1997023477A1 (fr)
ZA (1) ZA9610761B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039709A1 (fr) * 1998-02-07 1999-08-12 Knoll Aktiengesellschaft Formulation pharmaceutique liquide renfermant de la zotepine
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
US8906948B2 (en) 2008-09-06 2014-12-09 Bionevia, LLC Choline cocrystal of epalrestat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1247067A (en) * 1968-02-16 1971-09-22 Fujisawa Pharmaceutical Co Tricyclic enol ether compounds and the preparation thereof
JPH08145472A (ja) * 1994-11-17 1996-06-07 Tokyo Gas Co Ltd 温風暖房機

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1247067A (en) * 1968-02-16 1971-09-22 Fujisawa Pharmaceutical Co Tricyclic enol ether compounds and the preparation thereof
JPH08145472A (ja) * 1994-11-17 1996-06-07 Tokyo Gas Co Ltd 温風暖房機

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHEM.PHARM.BULL., vol. 26, no. 10, 1978, JAPAN, pages 3058 - 3070 *
CHEMICAL ABSTRACTS, vol. 125, no. 7, 1996, Columbus, Ohio, US; abstract no. 76242a, PETIT,M. ET AL.: "A COMPARAISON OF AN ATIPICAL AND TYPICAL ANTIPSYCHOTIC,ZOTEPINE" page 143; column 2; XP002026142 *
CHEMICAL ABSTRACTS, vol. 125, no. 7, 1996, Columbus, Ohio, US; abstract no. 76244c, NEEDHAM,P. ET AL.: "ZOTEPINE:" page 144; column 1; XP002026141 *
CHEMICAL ABSTRACTS, vol. 87, no. 27, 1977, Columbus, Ohio, US; abstract no. 84852m, page 583; XP002026140 *
CHEMICAL ABSTRACTS, vol. 90, no. 27, 1979, Columbus, Ohio, US; abstract no. 103793y, UEDA,I. ET AL.: "NEUROTROPIC AND PSYCHOTROPIC AGENTS.III." page 577; XP002026138 *
CHEMICAL ABSTRACTS, vol. 95, no. 27, 1981, Columbus, Ohio, US; abstract no. 97618e, page 637; XP002026139 *
FLEISCHHACKER,W ET AL.: "RESULTS OF AN OPEN PHASE II STUDY WITH ZOTEPINE", PHARMACOPSYCHIATRY, vol. 20, no. 1, February 1987 (1987-02-01), STUTTGART, pages 64 - 66, XP000618605 *
FLEISCHHAKKER ET AL.: "LOW DOSE ZOTEPINE IN THE MAINTENANCE TREATMENT OF SHIZOPHRENIA.", PHARMACOPSYCHIATRY, vol. 20, no. 1, February 1987 (1987-02-01), STUTTGART, pages 61 - 63, XP000618606 *
FLEISCHHAKKER,W ET AL.: "ZOTEPINE IN THE TREATMENT OF NEG. SYMPTOMS IN CHRONIC SCHIZOPHRENIS.", PHARMACOPSYCHIATRY, vol. 20, no. 1, February 1987 (1987-02-01), STTTGART, pages 58 - 60, XP000618607 *
PSYCHOPHARMACOL. BULL., vol. 32, no. 1, 1996, ENGL, pages 123 - 128 *
PSYCHOPHARMACOL.BULL., vol. 32, no. 1, 1996, ENGL., pages 81 - 87 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039709A1 (fr) * 1998-02-07 1999-08-12 Knoll Aktiengesellschaft Formulation pharmaceutique liquide renfermant de la zotepine
US6239165B1 (en) 1998-02-07 2001-05-29 Knoll Aktiengesellschaft Liquid pharmaceutical formulation containing zotepine
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
US9447056B2 (en) 2008-07-25 2016-09-20 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
US8906948B2 (en) 2008-09-06 2014-12-09 Bionevia, LLC Choline cocrystal of epalrestat
US10464912B2 (en) 2008-09-06 2019-11-05 Bionevia Pharmaceuticals, Inc. Choline cocrystal of epalrestat

Also Published As

Publication number Publication date
HRP960600A2 (en) 1998-02-28
ZA9610761B (en) 1998-06-22
GB9526264D0 (en) 1996-02-21
EP0874840A1 (fr) 1998-11-04
AU1195597A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
EP0814788B1 (fr) Amelioration de la tolerance au glucose
EP0866713B1 (fr) Supports d'administration pour medicaments analgesiques, anti-inflammatoires et antipyretiques contenant de l'oxyde nitreux et compositions pharmaceutiques contenant ces supports et ces medicaments
KR20090021169A (ko) Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
CA2966195C (fr) Amantadine par voie buccale dans le traitement des troubles de la demarche chez les patients atteints de la sclerose en plaques
EP1039900B1 (fr) Agents therapeutiques contenant sibutramine et orlistat
ES2199374T3 (es) Derivados de 1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina para reducir el nivel de acido urico en seres humanos.
EP0066918A1 (fr) Compositions anti-inflammatoires causant un dommage gastrique minimalisé
JPS59112948A (ja) コレステロ−ルレベル低下剤
JPH0489428A (ja) 多形核白血球活性化剤
JPS5938203B2 (ja) 補酵素ｑを主成分とする脳循環障害治療剤
EA001325B1 (ru) Способы лечения и профилактики интерстициального цистита
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
EP1162965A1 (fr) Procede de lutte contre le gain de poids associe a des medicaments therapeutiques
EP0190851B1 (fr) Composition anti-inflammatoire
WO1997023477A1 (fr) Derives de dibenzothiepine et compositions pharmaceutiques
US5292497A (en) Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate
HUT50440A (en) Process for producing pharmaceutical compositions for treating schizophrenia
WO2001000185A2 (fr) Agents therapeutiques
US4517309A (en) Method for the treatment of calcifying pancreatitis
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
CN100560075C (zh) 调节脂类代谢的药物
CA2214831A1 (fr) Utilisation pharmacologique de certains derives de la cystine
JPH07233062A (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
CN111166868A (zh) 一种用于治疗神经疾病和障碍的组合物
JPS645006B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA CN CZ GE HU IL JP KR LV MX NO NZ PL RO RU SG SI SK TR UA US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996943126

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97523274

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996943126

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996943126

Country of ref document: EP